Document is current
Any future updates will be listed below
-
Authors
Smilde, Bernard J.
Stockklausner, Clemens
Keen, Richard
Whittaker, Andrew
Bullock, Alex N.
von Delft, Annette
van Schoor, Natasja M.
Yu, Paul B.
Eekhoff, E. Marelise W.
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (821600)
- License Information
-
More Information
Article History
Received: 22 April 2022
Accepted: 24 May 2022
First Online: 1 June 2022
Declarations
:
: This study was approved by the Amsterdam UMC medical ethical board (2019.555). All procedures performed are in accordance with the ethical standards of the institutional and national research committees and with the 2013 version of the Helsinki declaration. Written consent will be obtained from each participant prior to collection of data.
: Not applicable.
: AW is a full-time employee of AstraZeneca UK Ltd. and may hold shares in the company. PBY is a cofounder of and holds stock in Keros Therapeutics, which develops therapies for hematologic and musculoskeletal diseases targeting bone morphogenetic protein and TGF-β signaling pathways, including fibrodysplasia ossificans progressiva. The interests of PBY are reviewed and managed by Brigham and Women’s Hospital in accordance with their conflict-of-interest policies. All other authors declare no conflicts of interest.
